Bleeding irregularities are one of the major reasons for discontinuation of oral
contraceptives (OCs), and therefore clinicians need to set expectations during consultations …

Objective The aim of this study is to compare the effect of ethinyl estradiol 0.03
mg/gestodene 0.075 mg (EE/GSD) with ethinylestradiol 0.03 mg/drospirenone 3 mg …

A cross-over study of two oral contraceptive formulations, containing 30 μg ethinylestradiol
in combination with 150 μg desogestrel (Marvelon®) or 75 μg gestodene (Femovan®), has …

BACKGROUND: The present study compared the efficacy and safety of a combined oral
contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest (EE/DNG) in …

The effect of two oral contraceptives containing 30 μg ethinylestradiol+ 75 μg gestodene or
30 μg ethinylestradiol+ 150 μg desogestrel upon various hormonal parameters were …

A comparison of cycle control, efficacy and tolerability of two oral contraceptive preparations
containing 20 μg ethinylestradiol combined with either 100 μg levonorgestrel (EE/LNG …

The newer progestogens gestodene, desogestrel and norgestimate were developed in an
attempt to produce agents with more selective progestational activity that would improve …

The aim of the trial was to demonstrate the contraceptive efficacy of a new low dose oral
contraceptive containing 20 μg ethinyl estradiol and 100 μg levonorgestrel and to observe …

Two triphasic oral contraceptives containing gestodene (GES)(a new progestogen) and
levonorgestrel (LNG) were compared with respect to contraceptive effect, cycle control …

Objective To evaluate the pharmacokinetics of a combined oral contraceptive (OC)
containing oestradiol valerate/dienogest (E2V/DNG) administered according to a four-phasic …